HR Execs on the Move

Health Scholars

www.healthscholars.com

 
Health Scholars is transforming clinical education and training. Our mission is to advance healthcare education through virtualization, making experience-based training scalable, accessible and affordable to both Healthcare and Public Safety providers.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Cole Sandau
Chief Executive Officer Profile

Similar Companies

United Medical Solutions

United Medical Solutions is a Idaho Falls, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alter G Inc

Alter G Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fremont, CA. To find more information about Alter G Inc, please visit www.alter-g.com

Orahealth USA

Orahealth USA is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mount Vernon Clinical Research

Mount Vernon Clinical Research is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.